The short version of Alpha-MSH fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-13 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
=== Disruptions to agrifood systems === Agrifood systems are exposed to shocks and stresses of various types that differ in nature and intensity, including those impair agrifood systems by disrupting the operations of related institutions, supply chains and actors. Agrifood markets are operating in an era marked by recurrent, increasingly severe and overlapping shocks, including extreme weather events, conflicts, pandemics, financial crises, disease outbreaks, and sharp increases in energy and agricultural input prices. These shocks have disrupted production, trade flows and markets, exposing vulnerabilities across food supply chains. In a highly interconnected global economy, disruptions originating in one region can rapidly propagate across borders, affecting food availability, affordability and accessibility far beyond the location of the initial shock.
A motor unit that rotates the evaporation flask or vial containing the user's sample. A vapor duct that is the axis for sample rotation, and is a vacuum-tight conduit for the vapor being drawn off the sample. A vacuum system, to substantially reduce the pressure within the evaporator system. A heated fluid bath (generally water) to heat the sample. A condenser with either a coil passing coolant, or a "cold finger" into which coolant mixtures such as dry ice and acetone are placed. A condensate-collecting flask at the bottom of the condenser, to catch the distilling solvent after it re-condenses. A mechanical or motorized mechanism to quickly lift the evaporation flask from the heating bath. The vacuum system used with rotary evaporators can be as simple as a water aspirator with a trap immersed in a cold bath (for non-toxic solvents), or as complex as a regulated mechanical vacuum pump with refrigerated trap. Glassware used in the vapor stream and condenser can be simple or complex, depending upon the goals of the evaporation, and any propensities the dissolved compounds might give to the mixture (e.g., to foam or "bump"). Commercial instruments are available that include the basic features, and various traps are manufactured to insert between the evaporation flask and the vapor duct. Modern equipment often adds features such as digital control of vacuum, digital display of temperature and rotational speed, and vapor temperature sensing.
=== R139w === One further single nucleotide polymorphism, found homozygous in 0% to 5% of different ethnic population, is leading to an amino acid exchange on position 139 from arginine to tryptophane. Furthermore, an alternative RNA splicing site is created leading to a loss of the quinone binding site. The variant protein of NQO1*3 has similar stability as its wild-type counterpart. The variation between the two is substrate specific and it has reduced activity for some substrates. It has been recently shown that the NQO1*3 polymorphism may also lead to reduced NQO1 protein expression.
He later returns to her house to retrieve a necklace Venetia gave him, and discovers that she has an estranged 15-year-old daughter who is well aware of her numerous affairs. Nicole's exact cause of death is not specified, but is said to be of natural causes.
Sources: en.wikipedia.org
=== Gina Cross === Dr. Gina Cross (voiced by Kathy Levin) is a Black Mesa scientist who first appears as the Holographic Assistant for Gordon Freeman in the Black Mesa's Hazard Course and then later as one half of the protagonists in Half-Life: Decay. In Decay, Cross is the one who delivers the GG-3883 crystal sample to the delivery system and then heads to an area below the test chamber, where Dr. Colette Green is stationed, to fix a jam in the lift that allows the specimen to be delivered up to Gordon. After the Resonance Cascade occurs, Cross teams up with Dr. Green to battle their way through the now alien-infested facility. They first escort Rosenberg to the surface to contact the military, and then under the guidance of Dr. Richard Keller, they succeed in starting a resonance reversal to help lessen the effects of the dimensional rift. In Half-Life: Blue Shift, Cross can briefly be seen on a security camera in the surveillance room, delivering the GG-3883 crystal. In Half-Life: Opposing Force, Adrian Shephard finds Cross's corpse in Xen after being teleported there by the Displacer Cannon, which implies that she died sometime after the events of Decay. Randy Pitchford, the president and CEO of Gearbox Software, had since confirmed this fate. However, Valve themselves never confirmed anything about Cross's fate after the events of Decay. Cross was originally planned to be Gordon Freeman's spouse as well as another playable character in the original Half-Life, but this idea was cut from the final game.
The beta decay of 3H to 3He releases an electron and an antineutrino, and about 18 keV of energy. This is a low-energy decay, so the radiation cannot permeate skin. Tritium is thus only hazardous if directly ingested or inhaled.
In that meeting they spoke of the limits that would never be crossed: neither the monarchy nor the "unity of Spain" would be questioned; no responsibilities would be demanded for what happened during Franco's Dictatorship; no provisional government would be formed to open a constituent process; "revolutionary" parties would not be legalized ─ here the military included the Communist Party, their bête noire since the civil war. In short, the process leading to the elections would always be under the control of the government. Once the limits were clarified, the Army's misgivings were dispelled and Suárez got the go-ahead for the process he was about to undertake.
Wound assessment is a component of wound management. As far as may be practical, the assessment is to be accomplished before prescribing any treatment plan. The objective is to collect information about the patient and about the wound, that may be relevant to planning and implementing the treatment.
=== Audiovisual work === After military service in World War I, Jones returned to Hallock where he worked as a mechanic while learning about electronics. Jones built a transmitter for the town's first radio station. He also invented a device to combine sound with motion pictures. This attracted the attention of local entrepreneur Joseph A. Numero of Minneapolis, Minnesota. Numero owned a company that manufactured audio equipment called Ultraphone Sound Systems Inc. and was later renamed Cinema Supplies Inc. He hired Jones in 1927 as an electrical engineer to improve the audio equipment made by his firm. Jones worked on converting silent movie projectors into audiovisual projectors. He also patented a ticket-dispensing machine for movie theaters.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.